Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(40%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_4
1
20%
Ph phase_2
1
20%
Ph phase_3
2
40%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Other(1)

Detailed Status

Active, not recruiting2
Completed2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

active_not_recruiting240%
completed240%
unknown120%

Recent Activity

2 active trials
Showing 5 of 5
completedphase_3

Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

NCT04060199
completedphase_2

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

NCT04956289
active_not_recruitingphase_3

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

NCT04768062
active_not_recruitingphase_4

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

NCT04687020
unknown

The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation

NCT04337112

Clinical Trials (5)

Showing 5 of 5 trials
NCT04060199Phase 3

Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

Completed
NCT04956289Phase 2

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

Completed
NCT04768062Phase 3

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Active Not Recruiting
NCT04687020Phase 4

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

Active Not Recruiting
NCT04337112

The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5